Role of transporters in the distribution of platinum-based drugs by Saliha Harrach & Giuliano Ciarimboli
MINI REVIEW
published: 24 April 2015
doi: 10.3389/fphar.2015.00085
Frontiers in Pharmacology | www.frontiersin.org 1 April 2015 | Volume 6 | Article 85
Edited by:
Harry P. De Koning,
University of Glasgow, UK
Reviewed by:
Stanislav Yanev,
Bulgarian Academy of Sciences,
Bulgaria
Andrei Adrian Tica,










This article was submitted to
Drug Metabolism and Transport,
a section of the journal
Frontiers in Pharmacology
Received: 27 February 2015
Paper pending published:
30 March 2015
Accepted: 02 April 2015
Published: 24 April 2015
Citation:
Harrach S and Ciarimboli G (2015)




Role of transporters in the
distribution of platinum-based drugs
Saliha Harrach 1 and Giuliano Ciarimboli 1, 2*
1 Experimental Nephrology, Medical Clinic D, University of Münster, University Hospital Münster, Münster, Germany,
2 Interdisciplinary Center for Clinical Research (IZKF), University of Münster, University Hospital Münster, Münster, Germany
Platinum derivatives used as chemotherapeutic drugs such as cisplatin and oxaliplatin
have a potent antitumor activity. However, severe side effects such as nephro-, oto-, and
neurotoxicity are associated with their use. Effects and side effects of platinum-based
drugs are in part caused by their transporter-mediated uptake in target and non target
cells. In this mini review, the transport systems involved in cellular handling of platinum
derivatives are illustrated, focusing on transporters for cisplatin. The copper transporter 1
seems to be of particular importance for cisplatin uptake in tumor cells, while the organic
cation transporter (OCT) 2, due to its specific organ distribution, may play a major
role in the development of undesired cisplatin side effects. In polarized cells, e.g., in
renal proximal tubule cells, apically expressed transporters, such as multidrug and toxin
extrusion protein 1, mediate secretion of cisplatin and in this way contribute to the
control of its toxic effects. Specific inhibition of cisplatin uptake transporters such as
the OCTs may be an attractive therapeutic option to reduce its toxicity, without impairing
its antitumor efficacy.
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In order to reach sufficiently high concentrations, intracellular active drugs must cross the plasma
membrane to reach their targets. This process, especially in the case of hydrophilic drugs, is medi-
ated by specialized plasma membrane proteins called transporters. It is well known that eﬄux
transporters are involved in the development of drug resistance (Renes et al., 2000). Only recently,
it has become evident that uptake transporters not only are able to mediate drug effects but also
their side effects (Ciarimboli, 2011). In this mini-review, we will focus on transporter systems for
platinum-based drugs.
Cisplatin was the first platinum-based drug that revolutionized the treatment of neoplas-
tic diseases. For example, before the introduction of cisplatin as chemotherapeutic agent, tes-
ticular cancer was associated with a survival rate of only 5%. Today, treatment of this cancer
with a combination of new surgical techniques and cisplatin chemotherapy allows to achieve
a cure rate of over 90% (Einhorn, 2002). Currently, cisplatin is widely used for the therapy
of solid tumors. However, its use is limited by severe side effects such as nephro- and oto-
toxicity and peripheral neurotoxicity (Rabik and Dolan, 2007). Therefore, there is a need to
put an effort in developing less toxic platinum derivatives. The US Food and Drug Admin-
istration has approved carboplatin and oxaliplatin as chemotherapeutic agents. Nevertheless,
because of its superior efficacy, cisplatin remains the first-line treatment for several solid
cancers.
Treatment with cisplatin causes an acute and/or chronic nephrotoxicity in about one-third
of patients even under co-treatment with diuretics and pre-hydration (Pabla and Dong, 2008).
The clinical manifestations of cisplatin nephrotoxicity are a decreased glomerular filtration rate,
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increased serum creatinine level, reduced serum magnesium and
potassium levels (Pabla and Dong, 2008), and the development of
proteinuria of tubular and glomerular origin (Daugaard, 1990).
There are striking interindividual differences in susceptibility to
nephrotoxicity (Goren et al., 1986).
Animal studies showed that cisplatin damages mainly the
proximal tubules (Dobyan et al., 1980), where the S3 seg-
ment is highly sensitive to cisplatin toxicity and undergoes
extensive necrosis in vivo (Price et al., 2004). In contrast,
carboplatin treatment rarely results in nephrotoxicity (Breg-
man and Williams, 1986; Yasumasu et al., 1992; Rabik and
Dolan, 2007) and nephrotoxicity has never been observed
with oxaliplatin, allowing its administration without hydration
(Cassidy and Misset, 2002).
Tumor therapy with cisplatin causes a hearing loss, which is an
unresolved clinical problem especially in pediatric patients (Skin-
ner, 2004). By early onset, cisplatin therapy may lead to a delayed
speech development with serious consequences for social and
educational development (Skinner, 2004). Ototoxicity appears
with an incidence between 23 and 50% in adults and greater than
50% in children (Rabik and Dolan, 2007). It manifests clinically
with bilateral symmetrical high-frequency sensorineural hearing
loss, ear pain or tinnitus (Reddel et al., 1982). In the cochlea cis-
platin accumulates in the hair cells of the basal turn of Corti
organ (where high-frequency sounds are processed), in the spi-
ral ganglion cells, and in the lateral wall tissues (spiral ligament
and stria vascularis) (Rybak and Ramkumar, 2007). Upon cis-
platin accumulation, these cells undergo apoptosis (Rybak and
Ramkumar, 2007). Carboplatin and oxaliplatin are much less
ototoxic than cisplatin (Musial-Bright et al., 2011). Interestingly,
intravenous application of oxaliplatin (16.6mg/kg) in guinea pigs
resulted in cochlear drug concentrations lower than those mea-
sured upon treatment with equimolar cisplatin (12.5mg/kg), sug-
gesting that lower cochlear oxaliplatin accumulation is the reason
for its lower ototoxicity compared with cisplatin (Hellberg et al.,
2009).
Most patients treated with cisplatin develop a dose-related
large fiber sensory neuropathy, caused by cisplatin accumulation
in the dorsal root ganglia (DRG) (Meijer et al., 1999; Albers et al.,
2011). The symptoms of peripheral neurotoxicity may appear
already 1 month after initiating treatment and include paresthe-
sia, ataxia, numbness, reduced vibration, and joint position sen-
sations and diminished or absent muscle stretch reflexes (Roelofs
et al., 1984; Thompson et al., 1984; Cano et al., 1998; Albers
et al., 2011). Cisplatin toxicity seems to affect large diameter neu-
rons and proprioceptive sensory modalities (reviewed in Screnci
and McKeage, 1999), where platinum accumulation within DRG
leads to atrophy or loss of peripheral sensory neurons (Liu et al.,
2009). Carboplatin is less neurotoxic than cisplatin. Neurotox-
icity appears in only 4–6% of patients after administration of
high-dose carboplatin therapy (Amptoulach and Tsavaris, 2011).
Conversely, antitumor treatment with oxaliplatin causes signif-
icant acute and chronic peripheral sensory neuropathy (Amp-
toulach and Tsavaris, 2011). Acute neurotoxic effects develop
in 85–95% of patients treated with oxaliplatin and may result
from the impairment of voltage-gated sodium channels, reduc-
tion in intracellular calcium and of growth-associated protein-43
expression, or induction of oxidative stress (Adelsberger et al.,
2000; Gamelin et al., 2002; Carozzi et al., 2010; Amptoulach and
Tsavaris, 2011; Takeshita et al., 2011). The symptoms of oxali-
platin neurotoxicity include paresthesia in the extremities and the
perioral region, and dysfunction of fine sensory-motor coordi-
nation (Cavaletti and Zanna, 2002; Hartmann and Lipp, 2003;
Amptoulach and Tsavaris, 2011). These symptoms are exacer-
bated by cold exposure (Amptoulach and Tsavaris, 2011). It is
evident that oxaliplatin neurotoxicity impairs quality of daily life.
The antitumor effects of platinum derivatives seem to derived
from the formation of intra- and inter-strand crosslinks with
DNA (Wang and Lippard, 2005).
Focusing on cisplatin, the molecular species involved in
this process seems to be aquaions, which are supposed to
be formed upon cytosolic cisplatin hydrolysis driven by the
lower intracellular Cl− concentration. The cisplatin aquaions are
strongly electrophilic and bind DNA and sulfhydryl groups of
proteins.
Since cisplatin is a hydrophilic drug (Houjou et al., 1996), it
cannot easily cross the plasmamembrane. In the kidneys cisplatin
is free filtered in the glomerulus and also secreted into the urine
(Jacobs et al., 1984). These observations suggested that the move-
ment of cisplatin through the plasma membrane is mediated by
transport proteins.
Copper Transporter 1 (Ctr1, Solute Carrier
31A1-SLC31A1)
Copper transporter 1 (Ctr1, Solute Carrier 31A1-SLC31A1) is
a membrane protein that plays a significant role in the cellular
cisplatin uptake (Holzer et al., 2004, 2006; Safaei and Howell,
2005; Larson et al., 2009). Down-regulation of Ctr1 extensively
reduced cisplatin uptake in yeast and inmouse embryonic fibrob-
lasts (Ishida et al., 2002; Lin et al., 2002). The natural substrate
of Ctr1 is monovalent copper (Cu+) (Ohrvik and Thiele, 2014).
Cu+ uptake by Ctr1 triggers transporter internalization. How-
ever, whether this phenomenon also happens upon cisplatin
transport is debated (Sinani et al., 2007; Tsai et al., 2014). As
observed for Cu+, cisplatin binds to Methionine-rich motifs of
the extracellular domain of Ctr1 (Ohrvik and Thiele, 2014). Ctr1
carries out vital physiological function supplying the cell with
copper, which is an essential cellular nutrient used in a broad
range of enzymatic reactions. Because of its important biologi-
cal role, Ctr1 is almost ubiquitously expressed and perhaps may
not be the decisive transporter for specific cisplatin toxicities.
Since several cell lines from human tumor samples express Ctr1-
mRNA (Ciarimboli et al., 2010), this transporter could represent
the uptake route of cisplatin in cancer cells. Indeed, high expres-
sion levels of Ctr1 have been associated with cisplatin therapeutic
success (Lee et al., 2011; Liang et al., 2012) whereas Ctr1 muta-
tions are associated with cisplatin resistance (Xu et al., 2012).
Ctr1 has been also associated with the cellular transport of car-
boplatin and oxaliplatin. However, cells with a genetic deletion of
Ctr1 show an uptake of oxaliplatin at concentrations higher than
2µM, suggesting the presence of another low-affinity oxaliplatin
transport system (Holzer et al., 2006).
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Copper Transporter 2 (Ctr2, SLC31A2)
Copper transporter 2 (Ctr2, SLC31A2) is a copper transport pro-
tein with substantial structural homology to Ctr1. Ctr2 is mainly
expressed in late endosomes and lysosomes (Blair et al., 2009),
where it probably mediates the eﬄux of copper under conditions
of low environmental copper concentration (van den Berghe
et al., 2007). A similar function of Ctr2 was proposed for cis-
platin (Blair et al., 2011). Studies in Ctr2-deficient mice suggested
that Ctr2 functions as an indirect regulator of Cu+-uptake and
intracellular flux by stabilizing the biosynthesis of cleaved Ctr1.
The cleaved Ctr1 is a transporter form which lacks metal binding
Methionine- and Histidine-rich motifs and of consequence has
decreased Cu+ and also cisplatin uptake function (Ohrvik et al.,
2013). Therefore, high expression of Ctr2 seems to be associated
with resistance to the cytotoxic effect of cisplatin (Blair et al.,
2009) and knockdown of Ctr2 was associated with an increased
cisplatin accumulation and cytotoxicity (Blair et al., 2009, 2011).
Copper-Transporting ATPase 1 and 2
(ATP7A and ATP7B)
The P-type copper-transporting ATPases ATP7A and ATP7B are
also involved in cellular cisplatin handling. These transporters
play an important role in regulating the cellular copper levels,
because too high intracellular copper concentrations are toxic for
the cell. Inactivation of these transporters, as present for example
in Menkes’ disease (inactivation of ATP7A) and in Wilson’s dis-
ease (inactivation of ATP7B), is associated with copper deficiency
because of impaired copper eﬄux from enterocytes into the blood
or massive cellular copper overload, respectively (Gupta and Lut-
senko, 2009). While ATP7A is mainly expressed in intestine,
choroid plexus, vascular smooth muscle and endothelial cells, as
well as in cerebrovascular endothelial cells (Lutsenko et al., 2007),
ATP7B is principally expressed in the liver and the brain (Lut-
senko et al., 2007). Regarding the transport of cisplatin, ATP7A
and ATP7B mediate its eﬄux from the cell or its distribution
to specific sub-cellular compartments (Katano et al., 2003, 2004;
Samimi et al., 2004a,b; Safaei et al., 2008; Safaei et al., 2012). For
this reason, the expression of these transporters is correlated with
cisplatin cellular sensitivity and resistance (Komatsu et al., 2000;
Nakagawa et al., 2008): ATP7B is stronger associated with the
acquisition of resistance than Ctr1 or ATP7A (Yoshizawa et al.,
2007; Mangala et al., 2009). Besides cisplatin, ATP7A and B trans-
porters also interact with carboplatin and oxaliplatin (Samimi
et al., 2004b; Martinez-Balibrea et al., 2009). Even though the
effects of ATP7A and B transporters on cisplatin cellular distribu-
tion are very similar to those observed for copper, platinum drugs
are not readily exported after vesicular sequestration (Samimi
et al., 2004b).
Interestingly, copper transport systems are expressed and
active in DRG, which are sensitive to toxicity from platinum
derivatives. Here, Ctr1 is expressed in large-sized neurons and
ATP7A in small DRG neurons (Ip et al., 2010), suggesting that
large neurons are especially sensitive and small neurons are
protected from toxic effects of platinum derivatives.
Organic Cation Transporters (OCT1-3,
SLC22A1-3)
A specific interaction of cisplatin with OCTs has also been
demonstrated (Ciarimboli et al., 2005; Yonezawa et al., 2005; Fil-
ipski et al., 2008). Since OCTs have a specific organ distribution,
with high renal expression, the cisplatin-OCT interaction is of
special interest to explain selective organ toxicity of cisplatin.
OCTs are highly expressed in excretory organs such as the liver
and the kidneys, where they mediate the electrogenic uptake of
their substrates in hepatocytes and proximal tubule cells, respec-
tively (Ciarimboli, 2008). OCTs are defined as polyspecific trans-
porters, because they can transport several unrelated substances.
The driving force for the cellular transport by OCTs is the elec-
trochemical gradient of the substrate (Ciarimboli and Schlat-
ter, 2005). In excretory organs, OCTs mediate the first step of
secretion process, consisting of substrate uptake through the
basolateral plasma membrane (the blood-faced part of plasma
membrane). The subsequent substrate eﬄux through the lumi-
nal membrane (the bile- or urine-faced part of plasma mem-
brane) is the final secretion step, resulting in a vectorial substrate
movement from the blood to the bile or urine in the liver or
kidneys (Figure 1), respectively. In humans the paralogs hOCT1
and hOCT2 are specifically expressed in the basolateral mem-
brane of hepatocytes and renal proximal tubule cells, respec-
tively (Koepsell, 2004). Cisplatin seems to interact preferentially
with hOCT2 (Ciarimboli et al., 2005), suggesting that hOCT2
is the critical transporter for renal cisplatin uptake in humans
(Figure 1). Also the second- and third generation platinum-
derivatives oxaliplatin (Yonezawa et al., 2006) and picoplatin
(More et al., 2010), respectively, are substrates of OCTs. For the
interpretation of translational studies, it is important to under-
line that the rodent OCT orthologs have a different organ distri-
bution and kinetic properties compared with human OCTs: for
example, in mice OCT1 is expressed in renal proximal tubules
at higher level than OCT2 (Schlatter et al., 2014). Competition
of OCT-mediated cisplatin transport is able to reduce cisplatin
uptake (Ciarimboli et al., 2010; Wehe et al., 2014) and toxicity
(Ciarimboli et al., 2005, 2010; Yonezawa et al., 2005) in vitro
and in vivo. OCT2 has been demonstrated to be expressed in
the mouse cochlea in hair cells of Corti organ and in the cells
of the stria vascularis (Ciarimboli et al., 2010) and in mouse
and human DRG (Sprowl et al., 2013), structures that are spe-
cially sensitive to toxicity by platinum-derivatives. In animal
models it has been demonstrated that OCTs are critical media-
tors of cisplatin ototoxicity (Ciarimboli et al., 2010) and oxali-
platin peripheral neurotoxicity (Sprowl et al., 2013). Currently,
the role of genetic variations of SLC22A2 for the development
of cisplatin-induced nephrotoxycity is debated: some publica-
tions describe an association of the SLC22A2 non-synonymous
single nucleotide polymorphism (SNP) 808 G/T (resulting in an
exchange of alanine to serine at position 270) with a protection
against cisplatin nephrotoxicity (Filipski et al., 2009; Zhang and
Zhou, 2012), other studies however could not confirm this find-
ing (Tzvetkov et al., 2011). Recent results suggest that the SNP
808 G/T confers a protection against cisplatin ototoxicity in a
pediatric population (Lanvers-Kaminsky et al., 2015). Therefore,
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FIGURE 1 | Transport systems involved in secretion of platinum
derivatives in human renal proximal tubules. Uptake of oxaliplatin
and cisplatin from the blood is mediated by hOCT2 expressed in the
basolateral plasma membrane. hMATE1, hMATE2-K, and Mdr2 in the
apical plasma membrane mediate the secretion of platinum derivatives
into the urine.
it could be assumed that inhibition of hOCT2 by a competi-
tor could prevent cisplatin-induced side effects. Indeed, there
are several indications that patient co-treatment with cimeti-
dine protects the kidneys from cisplatin nephrotoxicity (Sleijfer
et al., 1987; Zhang and Zhou, 2012). However, such a protec-
tive therapeutic option is acceptable, if the uptake of cisplatin
into target tumor cells is not compromised. In animal models
and in patients, it has been demonstrated that the expression
of OCTs in tumor cells is down-regulated by epigenetic modi-
fications (Schaeffeler et al., 2011; Chen et al., 2013; Yang et al.,
2013). Moreover, studies in an animal model have shown that co-
treatment with cimetidine did not change the antitumor efficacy
of cisplatin (Katsuda et al., 2010). For these reasons, inhibition
of OCTs remains an attractive option to protect patients from
cisplatin side effects.
Comparing the transport properties of OCTs and Ctr1, it
was underlined that Ctr1 is an equilibrative transporter. On
the other side, although OCTs are not active transporters
in the sense of their activity being directly dependent on
ATP (primary active) or a trans-membrane ion flux (sec-
ondary active), the plasma membrane potential creates both
an electrical and a concentration gradient for their cationic
substrates. This allows an accumulation of platinum deriva-
tives in the cells to intracellular concentrations exceeding the
extracellular level (Yonezawa and Inui, 2011). However, the
affinities of OCT2 and Ctr1 for cisplatin seem to be simi-
lar [11 (Filipski et al., 2008) and 17µM (Liang et al., 2009),
respectively].
While OCTs mediate the basolateral uptake of cisplatin in
renal proximal tubule cells, other transporters expressed in the
apical cell membrane are involved in the cisplatin secretion into
the urine (Figure 1).
Multidrug and Toxin Extrusion Protein 1
(MATE1, SLC47A1)
Several evidences indicate that MATE1 mediates secretion of
cisplatin into the urine. Mice with genetic deletion of MATE1
are more sensitive to cisplatin nephrotoxicity (Nakamura et al.,
2010). Furthermore, cell transfected with MATE1 displayed a
higher cisplatin uptake than control cells (Nakamura et al.,
2010). Interestingly, MATE1 and MATE2-K, another mem-
ber of MATE family which is solely expressed in human kid-
neys, seem to transport oxaliplatin with higher affinity than
cisplatin (Yokoo et al., 2007), offering a possible explana-
tion of the low oxaliplatin nephrotoxicity. As outlined above,
inhibition of OCT2 may be a protective strategy against cis-
platin nephrotoxicity. However, some inhibitors of OCT2 such
as cimetidine (Matsushima et al., 2009) and ondansetron (Li
et al., 2013) interact with higher potency with MATE1, block-
ing cisplatin eﬄux from the cells and potentially increasing
cisplatin renal toxicity. Indeed, co-treatment of mice with cis-
platin and cimetidine was effective in protecting the animals
from ototoxicity but not from nephrotoxicity (Ciarimboli et al.,
2010).
There are some investigations suggesting a role of novel
organic cation transporters (OCTNs) for oxaliplatin trans-
port. These transporters are expressed on the apical mem-
brane of renal proximal tubule cells (Ciarimboli, 2008) and
in rat DRGs (Jong et al., 2011). When transfected in human
embryonic kidney cells, rat and human OCTN1 and OCTN2
mediate significant oxaliplatin uptake (Jong et al., 2011), sug-
gesting that OCTNs are involved in oxaliplatin neurotoxic-
ity. Apart from these not directly ATP-dependent transporters,
multidrug resistance-associated protein 2 (Mrp2) transporter
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seems to be involved in the eﬄux of cisplatin and its conju-
gates from kidney cells, and for this reason to play an impor-
tant role for control of cisplatin renal toxicity (Wen et al.,
2014).
In conclusion, cellular transport of platinum derivatives is
mediated by several transport systems. Some transporters, such
as OCTs, are specifically expressed in organs, which are dam-
aged by antitumor therapy with platinum derivatives. For this
reason, theymay be a target for protective intervention. However,
an efficient protection can be only reached by specific inhibition
of OCTs.
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